patritumab deruxtecan investigational
Selected indexed studies
- Antibodies to watch in 2025. (MAbs, 2025) [PMID:39711140]
- Antibodies to watch in 2024. (MAbs, 2024) [PMID:38178784]
- Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy. (J Clin Oncol, 2025) [PMID:40554742]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy. (2025) pubmed
- Antibodies to watch in 2024. (2024) pubmed
- Antibodies to watch in 2025. (2025) pubmed
- Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial. (2023) pubmed
- HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors. (2025) pubmed
- Antibody-drug conjugates in lung cancer: dawn of a new era? (2023) pubmed
- Real-World Treatment Patterns and Clinical Outcomes Among Patients with Metastatic or Unresectable EGFR-Mutated Non-Small Cell Lung Cancer Previously Treated with Osimertinib and Platinum-Based Chemotherapy. (2024) pubmed
- HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC. (2023) pubmed